- Home
- AXSM vs FDS Comparison
AXSM vs FDS Comparison
Compare AXSM & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | FDS |
|---|---|---|
| Founded | 2012 | 1978 |
| Country | United States | United States |
| Employees | N/A | 6258 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.1B |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | AXSM | FDS |
|---|---|---|
| Price | $182.55 | $279.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 18 |
| Target Price | ★ $285.22 | $275.19 |
| AVG Volume (30 Days) | 552.2K | ★ 665.5K |
| Earning Date | 11-02-2026 | 09-30-2026 |
| Dividend Yield | N/A | ★ 1.72% |
| EPS Growth | ★ 38.56 | 11.79 |
| EPS | N/A | ★ 11.16 |
| Revenue | N/A | ★ $1,435,351,000.00 |
| Revenue This Year | $50.90 | $6.43 |
| Revenue Next Year | $60.63 | $5.85 |
| P/E Ratio | ★ N/A | $23.95 |
| Revenue Growth | N/A | ★ 6.31 |
| 52 Week Low | $117.30 | $185.00 |
| 52 Week High | $260.19 | $320.48 |
Technical Indicators
Market Signals| Indicator | AXSM | FDS |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 48.07 |
| Support Level | $179.00 | $195.87 |
| Resistance Level | $188.89 | $295.33 |
| Average True Range (ATR) | 7.88 | 10.97 |
| MACD | -2.07 | -1.25 |
| Stochastic Oscillator | 5.85 | 60.91 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.